Semaglutide
FDA status: FDA has approved products that contain semaglutide, including Ozempic, Rybelsus.
PubMed: 5,724 publications mention Semaglutide, 732 of them trials or reviews. Search PubMed
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. Aronne LJ et al. The New England journal of medicine, 2025. Clinical Trial, Phase III. PMID 40353578 · DOI
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. Wharton S et al. The New England journal of medicine, 2025. Clinical Trial, Phase II, Randomized Controlled Trial. PMID 40934115 · DOI
- Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Heise T et al. Diabetes care, 2023. Randomized Controlled Trial. PMID 36857477 · DOI
- Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Karagiannis T et al. Diabetologia, 2024. Systematic Review, Network Meta-Analysis. PMID 38613667 · DOI
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Marso SP et al. The New England journal of medicine, 2016. Randomized Controlled Trial. PMID 27633186 · DOI
ClinicalTrials.gov: 788 registered studies. See all studies
- NCT05486065 A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight (Phase 2), completed
- NCT05443334 A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice, completed
- NCT03985384 Semaglutide Treatment On Coronary Progression (Phase 4), completed
MedlinePlus drug information ↗FDA label (DailyMed) ↗RxNorm 1991302 ↗PubChem CID 56843331 ↗Wikipedia ↗





